GERN
Geron Corporation (NASDAQ)
Healthcare — Biotechnology
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Price History
Fundamentals
| Market Cap | $814.73M |
| P/E Ratio (TTM) | - |
| Forward P/E | 19.54 |
| EPS (TTM) | $-0.11 |
| Dividend Yield | - |
| Profit Margin | -34.32% |
| Revenue Growth | 30.90% |
| ROE | -27.07% |
| Debt/Equity | 53.28 |
| Recommendation | None |
| Analyst Target | $3.40 |
| Analysts | 5 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 70.7 |
| Beta | 0.60 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $2.01 |
| 52-Week Low | $1.04 |
| 50-Day Avg | $1.33 |
| 200-Day Avg | $1.39 |
| Avg Volume | $15.38M |
| Volume | $9.91M |
Performance Analysis
NEUTRALGERN presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:11 UTC
Back to Screener Export Report